Physician profile
Daniel Thomas Pucheril
NPI 1215298104
$4,932.39
in general payments reported to CMS, 2019-2025
13 companies · $2,960 in 2025
The $2,960 reported for 2025 was more than what 86% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.93 · 2020: $45.00 · 2021: $111 · 2022: $72.76 · 2023: $106 · 2024: $1,595 · 2025: $2,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,614 · Food and Beverage: $1,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,614.07 |
| Food and Beverage | $1,047.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Profound Medical Corp. | $2,473.88 | 2024-2025 | Tulsa-Pro |
| Histosonics, INC. | $1,552.40 | 2025 | |
| Procept Biorobotics Corporation | $183.72 | 2023-2025 | Aquabeam Robotic System |
| Olympus America INC. | $139.67 | 2025 | Cysto-Nephro Videoscope |
| Astellas Pharma US INC | $106.93 | 2019-2021 | |
| Intuitive Surgical, INC. | $101.25 | 2021-2024 | |
| Boston Scientific Corporation | $93.74 | 2025 | Spaceoar Vue System - 10ml |
| Calyxo, INC. | $74.86 | 2023 | Cvac Aspiration System |
| Abbvie INC. | $60.75 | 2022 | |
| Telix Pharmaceuticals | $50.48 | 2025 | Illuccix |
| Neotract INC. | $45.00 | 2020 | |
| Urogen Pharma, INC. | $27.50 | 2022-2023 | Jelmyto |
| Teleflex LLC | $22.21 | 2025 | Barrigel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Pucheril listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.